Ongoing research is focused on optimizing these approaches, including the development of highly selective α7nAChR agonists and positive allosteric modulators, with potential applications in arthritis, IBD, and neurodegenerative diseases involving central neuroinflammation. This evidence concerns the gene CHRNA7 and arthritic joint disease.